Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: LAGEVRIO
12.1 Mechanism of Action Molnupiravir is a prodrug with antiviral activity against SARS-CoV-2. It is metabolized to the cytidine nucleoside analogue, NHC which distributes into cells where NHC is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). NHC-TP incorporation (as NHC-monophosphate [NHC-MP]) into SARS-CoV-2 RNA by the viral RNA polymerase (nsp12) results in an accumulation of errors in the viral genome leading to inhibition of replication. The mechanism of action (known as viral error catastrophe or viral lethal mutagenesis) is supported by biochemical and cell culture data, studies of SARS-CoV-2 infection in animal models, and analyses of SARS-CoV-2 genome sequences in human subjects treated with LAGEVRIO.
Contraindications
6 documented side effects by frequency
No community discussions found for MOLNUPIRAVIR yet.
0 available comparisons
No comparisons yet.
Dosage Forms
Tablet
Route
Oral